Join the Zocor group to help and get support from people like you.
Zocor News (Page 2)
FDA Medwatch Alert: FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy; Still Advises Most Pregnant Patients Should Stop Taking Statins
What safety information is FDA announcing? The U.S. Food and Drug Administration (FDA) is requesting removal of its strongest warning against using cholesterol-lowering statin medicines in pregnant...
FDA Medwatch Alert: Red Yeast Rice by Doctor’s Best: Recall - Undeclared Lovastatin
ISSUE: Doctor’s Best is voluntarily recalling lot 3121005 (7379 bottles) of Red Yeast Rice dietary supplement, 600 mg Capsules, 120-count bottles to the retail level. Doctor’s Best Red Yeast Rice has ...
FDA Medwatch Alert: Statins and HIV or Hepatitis C Drugs: Drug Safety Communication - Interaction Increases Risk of Muscle Injury
ISSUE: FDA notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins ...
FDA Medwatch Alert: Statin Drugs - Drug Safety Communication: Class Labeling Change
ISSUE: FDA has approved important safety label changes for the class of cholesterol-lowering drugs known as statins. The changes include removal of routine monitoring of liver enzymes from drug...
FDA Medwatch Alert: Zocor (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations
Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor [UPDATED 12/15/2011]...
FDA Approves Combination Therapy Juvisync
SILVER SPRING, Md., Oct. 7, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription...
FDA Medwatch Alert: Zocor (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations
Simvastatin sold under the brand-name Zocor, as a single-ingredient generic product, and sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor [Posted 06/08/2011]...
FDA Medwatch Alert: Statin drugs and amyotrophic lateral sclerosis (ALS)
[Posted 09/30/2008] An FDA analysis provides new evidence that the use of statins does not increase incidence of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease often referred to as...
FDA Medwatch Alert: Ezetimibe/Simvastatin (Vytorin); Simvastatin (Zocor); and Ezetimibe (Zetia)
[Posted 08/21/2008] FDA informed healthcare professionals that the Agency is investigating a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial of a possible association...
FDA Medwatch Alert: Simvastatin Used With Amiodarone
[Posted 08/08/2008] FDA notified healthcare professionals of the risk of muscle injury, rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. This risk...
FDA Medwatch Alert: Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
[Posted 01/25/2008] FDA provided healthcare professionals with an early communication about an ongoing data review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Homozygous, High Cholesterol - Familial Heterozygous, Prevention of Cardiovascular Disease